A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
Soo Jin ParkSuk-Joon ChangDong Hoon SuhTae Wook KongHeekyoung SongTae Hun KimJae-Weon KimHee Seung KimSung-Jong LeePublished in: BMC cancer (2022)
ClinicalTrials.gov Identifier: NCT04678102 .